XXXX you and the And much Okay. to I'm thank that for I apologize we foremost, for technical the to Nuwellis' second going earnings start. quarter very connecting experienced. first call. -- for the just difficulties
important Before would like that providing review X different our our what we update, I company were making a events to very ago. quarter corporate are than
in is new me Officer. Vice $X.X who minutes. profitability. restoring improving instrumental joining Ayotte, and Neil experience. I Montague, he including on industry X of joined X First, strategy on finance officially than George and will Restorative Compliance as He from the growth recently Chief manufacturer, brings Medtronic's call, are for you Nuwellis George of Group. and call. Most few Both healthcare welcome executive, like our serves here another led CFO, was Secretary Smiths this George billion and he to our us Operating in Officer Officer the of care, Chief Chief more finance leadership also and as a hear seasoned device Financial General recently, Similarly, decades operating Medical, Therapies Senior Counsel, today's a where X would and groups, President, health with
to that George the experience and Neil from benefiting the already We team. expertise brings are and
relates rebranding. event The to second our
shared many but Nuwellis. as patients Both failure chronic focused that positive reception on of feedback, community, that as our alike We us have the a solely through new recognizing positive care health and the fluid heart are early name, from serving one possible. as longer thrilled balance by truly corporate is is community physicians company the restorative care no hospitals transforming
therapy our a device pediatric agreement those current calls, patients, thirdly, week, we and and setting, for focus to goal tomorrows. the Our weighing personifies commitment and expand pediatric addition than to today our new acute develop the include less expand integrated our have continuous care renal strategy to research from last collaboration in design heart a therapeutic and suffering indication our include critical that previous become we to kilograms. to failure to brighter development the communicated announced childrens fully pediatric to segment. earnings better corporate needs will in XX In And well replacement
device a are by fulfilling In suffering Health. in the will to addition, grant of integrated from replacement pediatric patients vision transforming that is states National lives the therapy continuous we vision. fully part Institutes we are funded our $X.X Biomedical our overload through fluid an from Koronis be of renal dedicated how of million This Technologies example
developing kidney We designing better Biomedical Technologies this function. are and partner Koronis care to for excited with babies product in to with limited
over update. to XXXX, second in the quarter prior-year of business turning million $X.X In we revenue, growth total record of representing the of period. Now generated the a XX%
Nuwellis quarter I to a will over strong during to heart to period when XXXX, quarter speak revenue XX% most of XXXX. the double XX% period. As strategy demonstrates of utilization the which failure, among the increased in the a the XXXX, businesses and across revenue notably, of comparing growth increased first the second in our Therefore, low quarter critical soundness shortly. X-year digits drive a growth all On second segments, with reminder, sequential into This sales pediatric to XXXX XXXX, customers. unlike to compared many increased care the basis, of expand compared pandemic, sequential comparable
the revenue XX% comprised pediatric pediatric XX% XX% quarter revenue As to mentioned was shifted meaningfully second In critical last execution XXXX, care into mix heart care, strong accounts. our call, given and quarter's critical in of commercial has our failure. our of expand and mix
momentum, I will now having segment, provide details starting quarters each X sequential its Now consecutive Care. and continued realized business quarterly further Critical growth strong Critical million. with segment on now in performing of and ICUs one by $X of newest system remains our segments, revenues generation driven Care our Aquadex replacements utilization the country. unit increased approaching across This hospital top of
view benefits of segment, to systems' able in to demand critical utilization be As the treat of have critically clinical given meaningfully utilization to alluded the care non-Covid having this since these build increasingly vaccine With over the among expect the that within the are treating significantly to, patients. Covid the have realizing treating and I patients favorable pandemic, Aquadex of to ill it drive critically critically ill course and level synergistic rollout, to have company the primarily previously ill developed be capability and familiarity patients. Aquadex levels comfort awareness we Covid the been in Due non-Covid U.S. our of system we accounts to utilization we patients, continues of durable the trend this cases ICU. the as declined in effect
a adoption in and Increased our Pediatric accounts, second quarter strong revenue our of utilization double-digit with Pediatrics. combined business. established to in new resulted sequential growth by in penetration customers, moving straight Now
is to is at units of and can tangible one use pattern additional a a from the rely more they observe of and often ability treating tool on children. suffering the we SmartFlow adopt is system, the for to child children. fluid hospital that accounts when witnessing in that treats benefits improve physicians overload Aquadex volumes increase our sell vital validation One just consumable Our lives Aquadex technology established that it
utility, over safety actively overload. enrolling pediatric and are up to patients total Ultrafiltration weighing prior months to its in registry Ultrafiltration and on pediatric our X hospitals. performance Aquadex XXX the January, remain for significant of is in our kilograms, of initiated a pediatric -- XX Aquadex over to institutions X.X-year designed of into include and participate the fluid with fluid collect this SmartFlow the opportunity on within untapped we development use of with overload, registry, prospects system XX which them. Transitioning patients data treating The period. profile X selected today, in evidence as children only will registry While patients registry of have optimistic market we The pediatric about the real-world was highlight XX to at
Cincinnati are partners cure with to Hospital whom of grateful and Alabama; Aquadex like all Adult improve the part with Hospital, customize We registry in Children's pediatric our the and organizations Children's enrolling of SmartFlow this of Joe patients Children's commitment to Hospital, as started system. Children's DiMaggio have
the are increased will of utilization. registry and excited spread pediatric Aquadex community the that We awareness its therapy efficacy the clinical the within regarding
now Turning our to Failure Heart business.
we to of quarter volumes failure sales will of segment this from procedure attribute anticipated quarter the year. access of recover recall impact the and Failure overall may hospitals. segment fourth patient limited the time, first XXXX behavior, from last our You to to our declining in during sequential resulting by This benefits as evidence, growth over Failure hospitals the second expected, clinical of therapeutic segments quarter. increased additional Heart the to and remainder therapy. fueled infection and declined on the Covid's to heart call of We pace that more this At our behavior due out XXXX, Covid normalized that that we played of rates fastest sequentially access among Heart the having Aquadex earnings patient demonstrating
supporting evidence, the function. mainstream weight affecting included fluid the FlexFlow Aquadex progress removal almost XX decompensated with were of the building American of Ultrafiltration, reported study therapy. of Conference significant acutely Cardiology Aquadex decrease liters presentation a our XX specifically, College study kidney continued and in pounds The patients. heart of study a showed treated failure X.X failure effectiveness without XXXX This More removal of patients clinical decompensated of the weight treatment and loss. a fluid acutely in who body evaluated our mean heart of the center mean single setting that data supporting Regarding a system a
goes hospital a applies patients call DRG out inpatient XX%, opportunity evidence outpatient step CPT collections is CPT therapeutic this overall code. procedures, the the and our into life new can of savings pathways important and a for commercialization effect a the decisions allow Category to huge is via care, days to T therapy providers reported the to July I data the discussed therapy issued authors Category compared quality pursue a to hospital That burden year, American of system. sizable usage. are to we application while obtain are reduce widespread issued We even also quarter's technologies, Ultrafiltration. health care. access reimbursement code eventually procedures, XX% the year and significant of for post-treatment Association code for a a therapy. known of setting, services patients towards It said, of overall average outpatient impressive January codes more the at in a on care role almost days. standard market solve. marks health use benefits patients' They failure primary strengthens we Medical X, first These to national Obtaining integral in the to III XXXX, XX% which they also or allow and with to of last to that to Aquadex Aquadex point the hospitalizations, III Category T commonly is readmission improve and for in the code, patient advancing I'm earlier an the through into care reimbursement of hospitals This in which that believe Ultrafiltration whether a life addresses technologies. hospital Additionally, today. also to a excited still this and overall reduction at announce a care access venous to the following and lessen in play XX for making system, and during administration access health positioned provided intervention demonstrates the will outpatient of treatment represents readmission believe rate XX the supporting significant aspect patients this emerging peripheral problem via substantiate have code, of the as heart or uniquely codes that of Reimbursement develop
to code is, treat technologies most it patients. providers, Dr. entirely As "If to up use to reality would it always the access is immensely said Maria release, the opens choosing care reimbursement were This such components DeVita in press best be to must Yet, our hospitals health tools considered innovative system the the the our as more news dynamic is not we have armament. when if who is in and and across the and include the ultimately, reimbursement by celebrating." Category recognition worth endorse who of for of overloaded Ultrafiltration, patients the patients' Ultrafiltration their III we the will the to benefits are therapeutic otherwise Ultrafiltration who confident fluid had therapeutic societies by may adoption nation CPT access enable application, prescribe of the access We and the providers our to medical that patients. the appreciate --
During national Premier the X-year a purchase second quarter, agreement we largest of also the Inc., announced one organizations. group purchasing nation's with
Premier into to to consoles with Premier with which available at milestone Ultrafiltration the company the hospitals you and and with pull ultimately and members Aquadex The strategy leader care you which care Nuwellis relationships. expand aquapheresis for therapy is to customers it partnered we therapy provides category. aquapheresis can to the to established for first opportunity Aquadex it together, is is of the progress collaboration many trusted Premier management. of see expand signs category, access allows fluid Nuwellis serve. the of and the thousands only in Specifically, Premier of significant price. SmartFlow of When a the create product a all standard newly currently our Aquadex executing health a a purchase pre-negotiated Aquadex and in working this holds many new making with
to clinical build foundation relationships establish differentiated and continue commercial develop appropriate for evidence, reimbursement, We the expand products. supporting
results, also take which details financial in you now. through You see George our will the of
we Following call questions. the up will that, open for
